These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Author: Hervás JV, Presas-Rodríguez S, Crespo-Cuevas AM, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C.
    Journal: Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599.
    Abstract:
    A risk for developing progressive multifocal leukoencephalopathy is a major barrier to natalizumab use. Extended dosing intervals have been proposed as a way to maintain therapeutic efficacy and reduce progressive multifocal leukoencephalopathy incidence. This is the first reported case of progressive multifocal leukoencephalopathy in a patient using an extended dosing regimen (300 mg/6 weeks). A close clinical and imaging monitoring allowed early detection, which is a major prognostic factor. A favorable outcome was seen with a therapy comprising plasma exchange therapy, mirtazapine, mefloquine and cidofovir. Further studies will be needed to assess the potential role of extended dosing intervals to improve prognosis in patients receiving natalizumab and also to measure its impact clinically and/or radiologically.
    [Abstract] [Full Text] [Related] [New Search]